Richard Smith

• Advising Syngenta on the sale of Syngenta Bioline Ltd to Union InVivo.
• Advising Universal Coal plc on A$24.5 million strategic investment by IchorCoal.
• Advising Adaptimmune Ltd on $104 million Series A financing.
• Advising Imperial Innovations Group plc on equity raising of £150 million by way of placing of ordinary shares.
• Advising GW Pharmaceuticals plc on US public offering of ADSs totalling $169.8 million.
• Advising GW Pharmaceuticals plc on follow-on offering of ADSs raising $101.1 million on Nasdaq.
• Advising GW Pharmaceuticals plc on its initial public offering on Nasdaq.
• Advising Elsevier on the sale of its UK science and technology division books list to Informa.
• Advising Content Ventures Ltd on the introduction of a new Luxembourg holding company by way of scheme of arrangement.
• Advising Imperial Innovations Group plc on equity raising of £140 million by way of rights issue of ordinary shares and issue of warrants to subscribe for class of partly paid convertible shares.
• Advising Haas TCM on the acquisition of Aeropia and RD Taylor & Company from Umeco plc.
• Advising Rhodia on the sale of its European specialty phosphates business to Thermphos International.
• Advising Rhodia on the sale of its polyurethane flame retardants business to Albermarle Corporation.
• Advising Apace Media plc on the sale of 50% of Balkan Media Group to MTG Broadcasting AB.
• Advising Vue Entertainment on the acquisition of the Warner Village cinema circuit.
• Advising Vue Entertainment on the acquisition of the Ster Century UK cinema circuit.
• Advising Infrastructure India plc on its establishment and admission to the Official List of the UK Listing Authority.
• Advising Imperial Innovations Group plc on its admission to AIM.
• Advising Worldwide Clinical Trials on the acquisition of Nottingham Clinical Research.

The College of Law, Chester

University of Sheffield

• England und Wales

• Law Society